This page shows the latest insulin degludec news and features for those working in and with pharma, biotech and healthcare.
Group sales barely moved in 2018 compared to the prior year, coming in at 112bn krone, with the GLP-1 portfolio’s growth offsetting declines in insulin products. ... 10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a
Xultophy (insulin degludec and liraglutide) which rocketed more than 150% in the first six months of the year to 720m krone. ... 80bn krone on price reductions, competition from generic long-acting insulins including insulin glargine, and cannibalisation
Victoza’s performance meant that Novo Nordisk was able to weather the pressure in the insulins market, which kept its overall insulin sales flat at DKK 14.66bn. ... This was despite growth for new long-acting insulin Tresiba (insulin degludec), which
insulin degludec/liraglutide).
Studies find insulin degludec advantage over insulin glargine. Novo Nordisk has filed new data to the FDA showing its long-acting insulin Tresiba is less likely to cause low blood sugar ... The Danish drugmaker wants the results of the DEVOTE trial -
The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is ... same day as rival therapy Xultophy, Novo
More from news
Approximately 12 fully matching, plus 55 partially matching documents found.
Vice president sales and marketing, Novo Nordisk. International marketing manager insulin analogues, Novo Nordisk. ... Not reporting it is a very big issue.”. Novo has attempted to address hypoglycaemia with the launch of its new insulin Tresiba
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...